Norrin Signaling for Blood-Retinal Barrier Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for retinal vascular diseases, such as retinopathy, are limited in efficacy and have transient effects, and there is a need for long-term stabilization of blood-retinal barriers and reduction of vascular leakage.
Innovation Solution
Administration of norrin protein to modulate the expression of specific genes, including BMP2, CLDN5, and VE-cadherin, to restore and stabilize the blood-retinal barrier by enhancing claudin-5 and VE-cadherin expression in retinal endothelial cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-VEGF treatments are used to treat retinal vascular diseases, then vascular leakage is reduced, but the therapeutic effect is transient and long-term stabilization is not achieved
Solution Approach 1:
The patent changes the molecular target from VEGF (anti-VEGF treatments) to Norrin protein, which activates the Wnt signaling pathway. This parameter change in the therapeutic agent fundamentally alters the mechanism of action, shifting from suppressing angiogenesis to stabilizing the blood-retinal barrier through Norrin-induced gene expression changes in retinal endothelial cells.
Solution Approach 2:
The patent establishes continuous therapeutic action by inducing sustained gene expression changes (BMP2, CLDN5, VE-cadherin) through Norrin protein administration. This continuous action maintains blood-retinal barrier integrity over time, eliminating the transient effect observed with anti-VEGF treatments.
2Productivity
If cytokines involved in permeability are up-regulated to compensate for ischemic tissue, then oxygen and nutrient delivery is improved, but vascular leakage and edema increase
Solution Approach 1:
The patent converts the harmful effect of ischemia-induced cytokine up-regulation into a beneficial outcome. By administering Norrin protein, the therapy stabilizes the blood-retinal barrier and reduces vascular leakage, thereby preventing the harmful edema and tissue damage that would otherwise result from uncontrolled cytokine-driven permeability changes.
Solution Approach 2:
The patent introduces Norrin protein as an intermediary substance that mediates between ischemic tissue and the vascular barrier. Norrin binds to Frizzled receptors on retinal endothelial cells, activating the Wnt signaling pathway to induce protective gene expression, thus preventing direct harmful interactions between ischemic cytokines and the blood-retinal barrier.
3Productivity
If VEGF is over-expressed to promote angiogenesis in ischemic tissue, then blood vessel formation is enhanced, but blood vessel strength and permeability control are compromised
Solution Approach 1:
Instead of suppressing VEGF (anti-VEGF approach), the patent inverts the strategy by activating Norrin protein, which promotes alternative angiogenic pathways through Wnt signaling. This inversion leads to the formation of stronger, more stable blood vessels with better permeability control, as Norrin-induced genes (BMP2, CLDN5, VE-cadherin) enhance vascular integrity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Norrin protein effectively increases the expression of genes that stabilize the blood-retinal barrier, reducing vascular leakage and edema, providing a more sustained therapeutic effect compared to anti-VEGF treatments.
Implementation Method 1
Norrin binds Fz4 with nanomolar affinity, and Frizzled 4 knockout mice exhibit abnormal vascular development of the retina. Norrin interaction with Fz4 is dependent on the cell surface receptor LRP5. Frizzled receptors are coupled to the β-catenin canonical signaling pathway.
Implementation Method 2
The inactivation of glycogen synthase kinase (GSK) 3β and Axin through frizzled receptor binding stabilizes β-catenin, which subsequently accumulates in the cell nucleus and activates the transduction of target genes.
Implementation Method 3
Norrin protein induces signals that regulate vascular development of vertebrate retina and controls important blood vessels in the ear. Norrin protein effectively increases the expression of genes that stabilize the blood-retinal barrier.
Implementation Method 4
Tight junctions have an organizing role in epithelial and endothelial polarization and establish an apico-lateral barrier to the diffusion of solutes through the intracellular space. Tight junctions also restrict the movement of lipids and membrane proteins between the apical and the basolateral membrane.
Implementation Method 5
The over-expression of vascular endothelial growth factor (VEGF) causes an increase in vessel permeability due to depletion of cell-to-cell adhesion molecules such as VE-cadherin and claudin-5. Norrin protein effectively increases the expression of genes that stabilize the blood-retinal barrier, reducing vascular leakage and edema.
Implementation Method 6
Norrin protein effectively increases the expression of genes that stabilize the blood-retinal barrier by enhancing claudin-5 and VE-cadherin expression in retinal endothelial cells.
Data Source
AI summary
A method is provided to increase the expression of the genes CASP3 and THBD; and decrease the expression of the genes COL18A1, CPB2, NPR1, OCLN, BMP2, CLCL6, IL12B, SELPLG, CX3CL1, CASP3, THBD, COL18A1, CPB2, NPR1, CLDN5, CLD3, PIGF, BDNF, CNTF, VEGF-A, CAM-1, PGF, FOX-01, FOX-04, PDGFB, TGFA, HGF, VE-Cadherin, or PLAU. As a result, conditions associated with expression of these genes are treated. Caspase 3 is encoded by CASP3 (GenBank assembly accession: GCA_000001405.22) and cleaves and activates caspases 6 and 7; and the protein itself is processed and activated by caspases 8, 9, and 10. Caspase 3 is the predominant caspase involved in the cleavage of amyloid-beta 4A precursor protein, which is associated with neuronal death in Alzheimer's disease and after spinal cord injury. As caspase 3 is implicated in apoptosis upregulation of CASP3 can be used to induce dysfunction cell removal.